Iovance Biotherapeutics Inc
IOVA1.750USD
-1.420-44.79%
收盤 05/09, 16:00（美東）報價延遲15分鐘
534.19M總市值
虧損本益比TTM
關於 Iovance Biotherapeutics Inc 公司
Iovance Biotherapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司開發並提供針對實體瘤癌症患者的腫瘤浸潤淋巴細胞 (TIL) 療法。其主要候選產品 Amtagvi (lifileucel) 是一種腫瘤衍生的自體 T 細胞免疫療法，用於治療之前用 PD-1 阻斷抗體治療的不可切除或轉移性黑色素瘤成年患者，如果 BRAF V600 突變陽性，則使用 BRAF 抑制劑（含或不含 MEK 抑制劑）。該公司還銷售用於 Amtagvi 治療方案的 Proleukin (aldesleukin)，一種白細胞介素-2 或 IL-2 產品。其開發渠道包括在實體瘤癌症的其他治療環境中對 TIL 細胞療法進行多中心試驗。Amtagvi 和 Proleukin 是治療方案的一部分，該方案還包括淋巴細胞清除。該公司還在開發使用 TIL 的下一代療法，例如轉基因 TIL 細胞療法。
公司簡介
公司代碼IOVA
公司名稱Iovance Biotherapeutics Inc
上市日期Jun 20, 2008
成立日期2017
CEODr. Frederick G. Vogt, J.D., Ph.D.
員工數量838
證券類型Ordinary Share
年結日Jun 20
公司地址825 Industrial Road
城市SAN CARLOS
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94070
電話16502607120
網址https://www.iovance.com/
公司代碼IOVA
上市日期Jun 20, 2008
成立日期2017
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
349.65K
+3.55%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
87.58K
+1.61%
Mr. Jean-Marc Bellemin
Mr. Jean-Marc Bellemin
Chief Financial Officer
Chief Financial Officer
56.20K
-8.97%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
349.65K
+3.55%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
87.58K
+1.61%
Mr. Jean-Marc Bellemin
Mr. Jean-Marc Bellemin
Chief Financial Officer
Chief Financial Officer
56.20K
-8.97%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月4日 週日
更新時間: 5月4日 週日
持股股東
股東類型
持股股東
股東統計
佔比
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.23%
MHR Fund Management LLC
7.31%
Perceptive Advisors LLC
6.62%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
63.28%
持股股東
股東統計
佔比
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.23%
MHR Fund Management LLC
7.31%
Perceptive Advisors LLC
6.62%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
63.28%
股東類型
股東統計
佔比
Investment Advisor
24.77%
Investment Advisor/Hedge Fund
21.77%
Private Equity
13.95%
Hedge Fund
8.74%
Venture Capital
8.50%
Research Firm
3.25%
Bank and Trust
0.70%
Pension Fund
0.54%
Individual Investor
0.31%
Other
17.47%
機構持股
更新時間: 3月4日 週二
更新時間: 3月4日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
658
278.41M
85.05%
-24.34M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
2023Q1
607
232.93M
108.05%
+12.27M
2022Q4
639
197.16M
124.92%
+7.22M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Quogue Capital L.L.C.
28.07M
8.56%
+5.00M
+21.68%
Feb 20, 2024
The Vanguard Group, Inc.
27.48M
8.38%
+210.50K
+0.77%
Dec 31, 2024
MHR Fund Management LLC
24.42M
7.45%
+420.00K
+1.75%
Dec 31, 2024
Perceptive Advisors LLC
22.11M
6.74%
-4.51M
-16.93%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
20.17M
6.15%
+1.46M
+7.80%
Dec 31, 2024
State Street Global Advisors (US)
12.25M
3.74%
-952.70K
-7.22%
Dec 31, 2024
Hood River Capital Management LLC
8.99M
2.74%
+846.94K
+10.40%
Dec 31, 2024
Soleus Capital Management, L.P.
6.56M
2%
-1.97M
-23.08%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.87M
1.79%
+222.43K
+3.94%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
5.83M
1.78%
-26.82K
-0.46%
Dec 31, 2024
查看更多
持股ETF
更新時間: 5月6日 週二
更新時間: 5月6日 週二
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
1.21%
WisdomTree BioRevolution Fund
0.76%
Virtus LifeSci Biotech Products ETF
0.69%
Range Cancer Immunotherapy ETF
0.6%
SPDR S&P Biotech ETF
0.29%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Biotechnology ETF
0.08%
Strive Small-Cap ETF
0.06%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比1.21%
WisdomTree BioRevolution Fund
佔比0.76%
Virtus LifeSci Biotech Products ETF
佔比0.69%
Range Cancer Immunotherapy ETF
佔比0.6%
SPDR S&P Biotech ETF
佔比0.29%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.18%
ProShares Ultra Nasdaq Biotechnology
佔比0.11%
Invesco Nasdaq Biotechnology ETF
佔比0.11%
iShares Biotechnology ETF
佔比0.08%
Strive Small-Cap ETF
佔比0.06%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據